RegulatoryOfficial
New and updated human medicine marketing authorisations in November 2026 (Ravimiamet)
🇪🇪 Ravimiamet · Wed 04 Nov 2026
Ravimiamet (Estonian State Agency of Medicines) published an overview of human medicines marketing authorisations newly granted and renewed/updated in late October and early November 2026. It is a routine administrative listing useful for tracking the Estonian national market status of products, with no specific safety action indicated.
Official source: Ravimiamet ↗
Summary written by VigiEye from the official notice. AI-assisted; check the source before acting.
More Regulatory
All →
RegulatoryCompany releaseBeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
BeyondSpring, Inc. · Fri 13 Nov 2026
RegulatoryCompany releaseImricor starts US launch of NorthStar iMR system after paediatric FDA clearances
🇺🇸 Imricor Medical Systems, Inc. · Fri 13 Nov 2026
RegulatoryCompany releaseBeyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
🇺🇸 Beyond Air, Inc. (XAIR) · Fri 13 Nov 2026
RegulatoryCompany releaseFDA sets 10 March 2027 goal date for Intellia's one-time hereditary angioedema gene-editing therapy
🇺🇸 Intellia Therapeutics, Inc. (NTLA) · Fri 13 Nov 2026
RegulatoryCompany releaseBeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
🇺🇸 BeyondSpring Inc. (BYSI) · Fri 13 Nov 2026
RegulatoryCompany releaseFDA grants NeOnc Type B meeting on accelerated approval path for intranasal NEO100
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Fri 13 Nov 2026